



WBMT Symposium on Cell Therapy

An international scientific convention with the Ramaiah Medical College Bangalore



21-22 November 2025 • Ramaiah Memorial Hospital

Bengaluru, India

DAY ONE - SYMPOSIUM PROGRAM. Friday, 21 November 2025

Time	Activity / Topics
08:30-08:40	Introductory note from Ramaiah Hospital BMT Director
	Inaugural Program / Welcome messages
08:40-08:45	WBMT President
08:45-08:50	Ramaiah Medical College Chairman
08:50-08:55	APBMT
08:55-09:00	Karnataka state official
	Introduction Program
09:00-09:10	WHO Global perspective of cellular therapies
09:10-09:20	Results of the WBMT Cellular Therapies Survey
09:20-09:35	Coffee Break
SESSION I:	Country Presentations: Landscape of CAR-T and other cellular therapies in individual countries
09:35-09:50	eGTR including the new cellular therapy registry
09:50-10:00	CAR-T in China
10:00-10:10	CAR-T in Southeast Asia
10:10-10:20	CAR-T in Japan and South Korea
10:20-10:30	CAR-T in EMRO (includes Pakistan & Bangladesh)
10:30-10:40	CAR-T in Latin America
10:40-10:50	CAR-T in India
10:50-11:00	CAR-T in developed countries
11:00-11:10	Discussion
SESSION II:	Setting up a CAR-T Program: A Framework for Delivery
11:10-11:25	Essential elements for the establishment of a CAR-T program – Clinical aspects
11:25-11:40	Essential elements for the establishment of a CAR-T program – Laboratory aspects
11:40:12:00	Roundtable Discussion
12:00-12:45?	Lunch
12:45-13:30? SESSION III:	Lunchtime Symposium The current role of hematopoietic cell transplants in the era of CAR-T therapies
SESSION III:	The current role of hematopoletic cell transplants in the era of CAR-1 therapies
13:30-13:50	ALL
13:50-14:10	
14:10-14:30	Myeloma B cell Lymphomas
14:30-15:00	Roundtable Discussion
15:00-15:15	Coffee Break
SESSION IV:	Current Advances in Hematopoietic cell Transplantation: Conditioning, GvHD and Infections
JESSION IV.	current Advances in Hematopoletic cen Transplantation. Conditioning, OVID and injections
45.45.45.25	Milest is a see in Conditioning and Codd Danscounting
15:15-15:35	What is new in Conditioning and GvHD prevention
15:35-15:55	GvHD prevention
15:55-16:15	Novel therapies for GvHD What is new in CMV?
16:55-16:15 SESSION V:	Early and Late complications after CAR-T cell therapy and its management
3E33IUN V.	Larry and Late complications after CAK-1 cell therapy and its management
16:15-16:30	Cytopenia
16:30-16:45	CRS
16:45-17:00	ICANS and other neurologic complications
17:00-17:15	Secondary tumours and other complications
17:15-17:45	Roundtable Discussion
17:45-17:55	Quiz for students
17:55-19:25	Evening Symposium

DAY TWO - SYMPOSIUM PROGRAM. Saturday, 22 November 2025

Time	Activity / Topics
	Morning Symposium
SESSION VI:	CAR-T manufacturing
08:30-08:45	Point of care CAR-T manufacturing: Barcelona
08:45-09:00	Low-cost manufacturing: Indian experience from both companies - Part I
09:00-09:15	Low-cost manufacturing: Indian experience from both companies - Part II
09:15-09:30	The Brazil experience
09:30-10:00	Roundtable Discussion
10:00-10:15	Coffee Break
SESSION VII:	Training and organizational issues
10:15-10:30	Training Physicians / Training the Healthcare Team
10:30-10:45	Organizational and operational changes with increasing CAR-T utilization
10:45-11:00	Referral pathways and post CAR-T care networks
11:00-11:15	Roundtable Discussion
SESSION VIII:	How to achieve the optimal Apheresis Product
11:15-11:30	Parameters determining optimal apheresis product
11:30-11:45	How to harmonize quality criteria
11:45-12:15	Roundtable Discussion
12:15-13:30	Lunch
12:15-13:30	Lunchtime Symposium
SESSION IX:	Regulatory aspects, Biovigilance and Accreditation
13:30-13:50	Introduction to current worldwide regulatory frameworks – differences in worldwide regulation and
13.30-13.30	attempts at harmonization
13:50-14:10	WHO ECBS document on harmonization of regulation
14:10-14:30	Inspection and Accreditation
SESSION X:	Moving beyond CAR-T
14:30-14:45	Gene therapy vs transplant in sickle cell
14:45-15:00	
15:00-15:15	Gene therapy vs transplant in thalassemia Gene therapy in haemophilia
15:15-15:30	Coffee Break
SESSION XI:	Expanding the Landscape for CAR-T therapies
3233101 1 XII.	Expanding the Editascape for CAR 1 therapies
15:30-15:45	CAR-T cells for autoimmune diseases
15:45-16:00	CAR-T for T cell Leukemia/Lymphomas
16:00-16:15	CAR-T for Myeloid Malignancies
16:15-16:25	Awarding ceremony for quiz winners
16:25-16:30	Concluding Remarks
16:30-18:00	Evening Symposium II